Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Intravenous Once-Daily BuCy 2 With Pharmacokinetic (PK)-Guided Dose Adjustment As Conditioning Regimen For AML Patients In First Complete Remission

Felipe Suarez, MD, Philippe Bourget, PhD, Emilio Paolo Alessandrino, MD, Mario Regazzi, PhD, Gérard Socié, MD, PhD, Mauricette Michallet, MD, PhD, Jérôme Guitton, PHD, Sebastien Wittnebel, MD, Angelo Paci, PHD, Didier Blaise, MD, Bénédicte Devictor, PHD, Ana Berceanu, MD, Véronique Kemmel, PHD, Jorge Sierra, MD, PhD, Maria Estela Moreno Martinez, PHD, Ambroise Marcais, MD, Alexandre Amin, PHD, Anna Amelia Colombo, MD, Francesco Ripamonti, MD, de Latour Régis Peffault, MD, Nathalie Dhedin, MD, Alienor Xhaard, MD, Hélène Labussière-Wallet, MD, Franck E Nicolini, MD, PhD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Xavier Thomas, MD, Jean-Henri Bourhis, MD, PhD, Gonzalo Ferrini, PHD, Sabine Furst, MD, Bruno Lioure, MD, Rodrigo Martino, MD, PhD, Mireia Riba, PH, Anna Feliu, PHD, Carole Levrault, Marcello Riggi, MD, PhD, Christine Ta Thanh Minh, MD

Blood (2013) 122 (21): 4566.

https://doi.org/10.1182/blood.V122.21.4566.4566

Published: 2013

Journal Articles

Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan.

Marco Zecca, Riccardo Masetti, Adriana Balduzzi, Franca Fagioli, Giorgio Dini, Chiara Messina, Attilio Rovelli, Luca Lo Nigro, Mario Regazzi, Giuseppe Basso, Andrea Pession, Arcangelo Prete, Franco Locatelli

Blood (2009) 114 (22): 2288.

https://doi.org/10.1182/blood.V114.22.2288.2288

Published: 2009

Journal Articles

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up

Blood (2008) 112 (11): 1.

https://doi.org/10.1182/blood.V112.11.1.1

Published: 2008

Journal Articles

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Mario Regazzi, Michela Montagna, Antonia Avanzini, Barbara Scarpati, Anna Colosimo, Silvio Veronese, Alessandra Tedeschi, Sara Miqueleiz, Francesca Ricci, Liliana Intropido, Enrica Morra, Marco Montillo

Blood (2005) 106 (11): 2962.

https://doi.org/10.1182/blood.V106.11.2962.2962

Published: 2005

Journal Articles

Intravenous (i.v.) or Oral (os) Busulphan (BUS) in Children Prior to Autologous (Auto) or Allogeneic (Allo) Stem Cell Transplantation (SCT): Pharmacokinetics (PK), Toxicity and Compliance.

Arcangelo Prete, MD, Antonella Bartoli, MD, Claudia Castellini, MD, Roberto Rondelli, MD, Riccardo Masetti, MD, Andrea Pession, MD, Mario Regazzi-Bonora, MD

Blood (2005) 106 (11): 5320.

https://doi.org/10.1182/blood.V106.11.5320.5320

Published: 2005

Journal Articles

Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial

Blood (2005) 105 (1): 410–419.

https://doi.org/10.1182/blood-2004-05-1944

Published: 2005

Journal Articles

Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia.

Marco Montillo, MD, Alessandra Tedeschi, MD, Valentina Rossi, MD, Anna Maria Cafro, MD, Roberto Cairoli, MD, Silvio Veronese, PhD, Barbara Scarpati, PhD, Renata Farioli, PhD, Mario Regazzi, MD, Marcello Gambacorta, MD, Enrica Morra, MD

Blood (2004) 104 (11): 479.

https://doi.org/10.1182/blood.V104.11.479.479

Published: 2004

Journal Articles

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

Marco Zecca, Bruno Nobili, Ugo Ramenghi, Silverio Perrotta, Giovanni Amendola, Pasquale Rosito, Momcilo Jankovic, Paolo Pierani, Piero De Stefano, Mario Regazzi Bonora, Franco Locatelli

Blood (2003) 101 (10): 3857–3861.

https://doi.org/10.1182/blood-2002-11-3547

Published: 2003

NARROW

Intravenous Once-Daily BuCy 2 With Pharmacokinetic (PK)-Guided Dose Adjustment As Conditioning Regimen For AML Patients In First Complete Remission

Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan.

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up

Low Dose Rituximab in Adult Patients with Idiopathic Thrombocytopenic Purpura.

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Intravenous (i.v.) or Oral (os) Busulphan (BUS) in Children Prior to Autologous (Auto) or Allogeneic (Allo) Stem Cell Transplantation (SCT): Pharmacokinetics (PK), Toxicity and Compliance.

Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial

Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia.

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only